🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Global Guidelines on Pancreatic Cystic Neoplasms — we’re almost there! Final official in-person meeting today in San Diego. Stay tuned for the next steps. IAP EPC-Europ Pancr Club AHPBA E-AHPBA The Pancreas Club my_UEG Japanese Society of HBP Surgery IHPBA Marco Del Chiaro

First sham-controlled minor papilla endoscopic sphincterotomy trial — the SHARP trial — finds no benefit. Practice change ahead 🛑. GIs can skip risky sphincterotomy for acute pancreatitis and pancreas divisum patients. #DDW2025 @DDWmeeting OHSU Gastroenterology & Hepatology Pitt Division of GI, Hepatology & Nutrition

The future of urine #CytoPath; Dr. Sigfred Lajara of UPMC Pathology presenting “AIxMed: Enhancing Diagnostic Accuracy in Bladder Cancer Detection with Al-Assisted Urine Cytology” during the 22nd annual #IACcongress in Comune di Firenze

Just published in *The Journal of Pathology* our new investigation on mucinous cystic neoplasms (MCN) and simple mucinous cysts (SMC) of the pancreas (a new precursor of pancreatic cancer!) …thsocjournals.onlinelibrary.wiley.com/doi/10.1002/pa…

Online today in nature - our latest study led by superstar postdoc Gilles Rademaker detailing the role of PSCK9 in driving sterol dependent metastatic organ choice in pancreatic cancer nature.com/articles/s4158… full text available here 👉 rdcu.be/em0VG and thread 👇

Thank you to everyone who joined us for the 2025 Pathology Annual Research Day & Retreat on May 28! 👏We had an inspiring day of collaboration, innovation, and outstanding presentations, capped by an amazing keynote from Dr. Eric Duncavage of Washington Universit University of Pittsburgh UPMC Pathology Residency Program

Join us in Pittsburgh for the 20th PancreasFest July 24-25 at William Pitt Union caper-pancreas.org/pancreasfest

How many whole slides or TMAs does it take to properly assess the 3D cellular heterogeneity of a single tumor? Many! Read about 2D vs. 3D multi-omic assessments of tissues and tumors here: cell.com/cell-reports-m…

PIVOT is a very useful open source tool from Ashley Kiemen André Forjaz Denis Wirtz and colleagues at Johns Hopkins Kimmel Cancer Center that allows for co-registration and integration of multi-omic spatial data (eg, Visium, cyclicIF, imaging mass cytometry). Preprint: biorxiv.org/content/10.110…

New #JITC article: Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma bit.ly/4lcxHLC Ryan C. Augustin Aatur Singhi, MD PhD Carsten Krieg Riyue Sunny Bao, PhD

Journalist and host Alisyn Camerota teams up with Cindy Price Gavin and PanCAN's Julie Fleshman for the exciting debut of the PancChat Podcast! After 9 years on Twitter/X, this compelling bi-monthly series is now available on all major podcast platforms: youtu.be/jcR241He74g

Amazing article by Siddhartha Mukherjee on the promises and perils of cancer early detection. Really resonated with me as I touched on several of the themes discussed here in my talk at the G7 conference on poor prognosis cancers. newyorker.com/magazine/2025/…

🚨 BREAKING: #FORTITUDE101 Trial Positive 📢 Bemarituzumab + chemo shows significant OS benefit in FGFR2b+ advanced #gastric & GEJ cancer (HER2–) in 1L setting 🧪 Target: FGFR2b (IHC 2+/3+ in ≥10%) 📈 Improved OS at pre-specified interim ⚠️ AE: Ocular toxicity (keratitis, dry

#QuPath 6.0 has absolutely the best extensions EVER. Check these out - especially the #instanSeg #deepLearning model for #cell #segmentation!! and yes, we also like great GUI + seamless scripting modules for more advanced programming experience! 🤩

Joint EPC-Europ Pancr Club and European Society of Pathology (ESP) Postgraduate Course at EPC meeting in Düsseldorf #EPC2025 Incomparable Claudio Luchini explaining the genetic basis of PDAC precursors

🔬 Who Should Get Screened for Pancreatic Cancer? Insights from #ESMOGI25 🔎 📌 High-Risk Germline Mutations 🧬 STK11 (Peutz-Jeghers): RR ~132 | Lifetime risk: 11–36% 🧬 PRSS1 (Hereditary Pancreatitis): RR 53–87 | Risk up to 55% by age 70 🧬 CDKN2A (FAMMM): RR 20–40 | Risk 17–25%

I try, often unsuccessfully, to not post while on vacation but this is just too important. Hot of the Arvind Dasari, MD, MS et al. press. New SEER data. Increasing incidence and prevalence, owing to earlier and likely largely incidental diagnoses. Improving OS too🙂 jamanetwork.com/journals/jaman…

ICYMI: MRA recently hosted an MRA Meet-Up webinar - "Oncolytic Immunotherapy, Clinical Trials, & the Emerging RP1 Treatment", featuring Dr. Yana Najjar of UPMC Hillman Cancer Center. Watch the recording here: curemelanoma.org/blog/mra-meet-…

DNA methylation goes spatial! Introducing Spatial-DMT: a technology that co-profiles DNA methylation and transcriptome in the same tissue section. A fantastic collaboration with Wanding Zhou lab. Kudos to Chin Nien Lee Chin Nien Lee and Hongxiang Fu! biorxiv.org/content/10.110…

PanCAN is proud to announce new appointments and transitions within its Board of Directors and Scientific and Medical Advisory Board (SMAB). Joining the Board this year is Jon Mahrt, Chief Executive Officer of Optum Rx and Chief Growth Officer of Optum, a leading health